VIVJOA® is a prescription medication approved by the FDA for the treatment of recurrent vulvovaginal candidiasis (RVVC) in non-pregnant women. Its main ingredient, oteseconazole, inhibits the growth and spread of Candida fungi that cause yeast infections. VIVJOA® is highly effective in reducing the frequency of RVVC, with a recommended dose of one suppository inserted vaginally once a week for up to six months.